66th ASH Annual Meeting: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Genes, Cells and Algorithms: Novel Methods of Predicting Progression in MGUS and SMM

Symposia: MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological Oral and Poster Abstracts
Oral

Research, Clinical trials, Adult, Translational Research, Genetic Disorders, Plasma Cell Disorders, Clinical Research, Bioinformatics, Genomics, Diseases, Lymphoid Malignancies, Computational biology, Biological Processes, Technology and Procedures, Study Population, Human, Measurable Residual Disease , Omics technologies

Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina)

Moderators:

Sæmundur Rögnvaldsson, MD, and Malin Hultcrantz, Memorial Sloan Kettering Cancer Center

Disclosures:

Rögnvaldsson: Siemens: Honoraria; Johnson and Johnson: Honoraria.

Precursor conditions such as MGUS and smoldering Multiple Myeloma do not always progress towards clinically active Multiple Myeloma. Ongoing efforts to unveil the genetic and cellular mechanisms modifying/defining risk of progression is an ongoing very important question and novel research findings will be addressed in detail in this session.

4:30 PM

1015

Differential Detection of Clonal Bone Marrow Plasma Cells in IgA Vs. IgG Monoclonal Gammopathy of Undetermined Significance and Its Association with Disease Progression

Jon Thorir Oskarsson¹^*, Sæmundur Rögnvaldsson, MD^1,2^*, Sigrun Thorsteinsdottir, MD, PhD^1,3, Andri Olafsson¹^*, Elias Eythorsson, MD, PhD²^*, Asbjorn Jonsson, MD⁴^*, Brynjar Vidarsson, MD²^*, Pall T. Onundarson, MD², Bjarni Agnarsson, MD²^*, Margret Sigurdardottir, MD²^*, Ingunn Thorsteinsdottir, MD, PhD²^*, Isleifur Olafsson, MD, PhD²^*, Stephen J. Harding, PhD⁵, Brian G.M. Durie⁶, Thorvardur Jon Love, MD, PhD^1,2^* and Sigurdur Y Kristinsson^1,2

¹Faculty of Medicine, University of Iceland, Reykjavik, Iceland
²Landspitali, The National University Hospital of Iceland, Reykjavik, Iceland
³Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
⁴Akureyri Hospital, Akureyri, Iceland
⁵The Binding Site Inc., Birmingham, United Kingdom
⁶Cedars-Sinai Medical Center, Los Angeles, CA

4:45 PM

1016

Plasma Cell Specific cfDNA Methylation Patterns Differentiate MGUS, SMM and MM and Predict Biochemical and Clinical Progression to MM

Moshe E Gatt, MD¹, Ilana E Fox-Fisher, MD PhD²^*, Omer Weinstein³^*, Sheina Piyanzin⁴^*, Daniel Cohen⁵^*, Benjamin Glaser⁶^*, Ruth Shemer⁴^*, Eyal Lebel⁷^* and Yuval Dor⁸^*

¹Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University, Jerusalem, Israel
²Department of Developmental Biology and Cancer Research, Hebrew University, Jerusalem, --- Select One ---, Israel
³Faculty of Medicine, Hebrew University, Jerusalem, --- Select One ---, Israel
⁴Hebrew University, JERUSALEM, ISR
⁵Hebrew University, Jerusalem, israel, Israel
⁶Faculty of Medicine, Hebrew University, Jerusalm, Israel
⁷Hadassah Medical Center, Jerusalem, ISR
⁸Department of Developmental Biology and Cancer Research, Hebrew University, JERUSALEM, ISR

5:00 PM

1017

Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants

Floris Chabrun, PhD, PharmD¹^*, Daniel Schwartz, PhD^1,2^*, Susanna Gentile¹^*, Tulika R Gupta, PhD^1,2^*, Noelia Collado Gisbert³^*, Esperanza Martín-Sánchez³^*, Rosalinda Termini³^*, Jacqueline F Perry¹^*, Annie Cowan, BA¹^*, Federico Ferrari, PhD^1,4^*, Samuel Freeman, PhD⁵^*, Robert A. Redd, MS⁶^*, Vidhi Patel, BS, RRT¹^*, Patrick Costello, MS¹^*, Catherine Tobia, MS¹^*, Romanos Sklavenitis-Pistofidis, MD^1,7, Habib El-Khoury, MD^1,8^*, Michael Timonian, MD¹^*, David J Lee, MD¹^*, Elizabeth D. Lightbody, PhD¹, Hadley Barr, BSc¹^*, Priya Kaur, BS¹^*, Katelyn Downey, MS¹^*, Sally Phan¹^*, Maya Patel, MHA¹^*, Jennifer Lamb, BS¹^*, Nana Ama Boadi-Acheampong, BS¹^*, Foteini Theodorakakou, MD⁹^*, Despina Fotiou, MD⁹^*, Christine-Ivy Liacos, MS⁹^*, Selina J Chavda, MBBS, BSc, MRCP¹⁰^*, Louise Ainley, BMBCh¹¹^*, Elizabeth K. O'Donnell, MD¹, Catherine R. Marinac, PhD^1,12, Gad Getz, PhD^7,13^*, Omar Nadeem, MD^12,14, Kwee Yong, MD, PhD¹⁵, Efstathios Kastritis, MD¹⁶^*, Meletios Dimopoulos, MD⁹, Jesús F. San-Miguel, MD, PhD³, Bruno Paiva, PhD³^*, Lorenzo Trippa, PhD⁶^* and Irene Ghobrial, MD^1,12

¹Dana-Farber Cancer Institute, Boston, MA
²Harvard T.H. Chan School of Public Health, Boston, MA
³Cancer Center Clinica Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IdiSNA), CIBER-ONC numbers CB16/12/00369 and CB16/12/00489, Pamplona, Spain
⁴Biostatistics and Research Decision Sciences, Merck & Co, Rahway, NJ
⁵Bioinformatics Program, Broad Institute of MIT and Harvard, Cambridge, MA
⁶Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
⁷Broad Institute of MIT and Harvard, Cambridge, MA
⁸University of Chicago Medical Center, Chicago, IL
⁹Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
¹⁰University College London Hospitals NHS Foundation Trust, London, United Kingdom
¹¹Cancer Institute, University College London, London, United Kingdom
¹²Harvard Medical School, Boston, MA
¹³Krantz Family Center for Cancer Research and Dept. of Pathology, Massachusetts General Hospital, Boston, MA
¹⁴Center for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA
¹⁵University College London, London, United Kingdom
¹⁶Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Voula,Athens, AL, Greece

5:15 PM

1018

Differentiating between MM like Smoldering Myeloma (SMM) and Non-Progressor SMM

Anil Aktas-Samur, PhD^1,2^*, Mariateresa Fulciniti, PhD², Parth Shah, MD³^*, Sanika Derebail, MS⁴^*, Raphael E. Szalat, MD, PhD⁵, Jill Corre, PharmD, PhD⁶^*, Kenneth C. Anderson, MD⁷, Giovanni Parmigiani, PhD⁴^*, Herve Avet-Loiseau, MD, PhD⁸^*, Mehmet K. Samur, PhD^9,10 and Nikhil C. Munshi, MD^7,11

¹Medical Oncology, Dana-Farber Cancer Institute & Harvard Medical School, Boston, MA
²Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
³Dartmouth-Hitchcock Medical Center, Lebanon, NH
⁴Dana Farber Cancer Institute, Boston, MA
⁵Section of Hematology and Medical Oncology, Boston Medical Center, Boston, MA
⁶Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
⁷Dana-Farber Cancer Institute, The Jerome Lipper Multiple Myeloma Center, Boston, MA
⁸Institut universitaire du cancer de Toulouse Oncopole, Toulouse, France
⁹Dana-Farber Cancer Institute, Harvard Medical School, Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Boston, MA
¹⁰Department of Data Science, Harvard TH Chan School of Public Health, Dana-Farber Cancer Institute, Boston, MA
¹¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

5:30 PM

1019

A 1,000-Genome Map for Multiple Myeloma and Its Precursor Stages, and Its Impact on Clinical Outcome

Jean-Baptiste Alberge, PhD^1,2,3, Ankit K. Dutta, PhD^1,2,3^*, Andrea Poletti^1,4^*, Tim H.H. Coorens, PhD³^*, Elizabeth D. Lightbody, PhD^1,2,3, Rosa Toenges, MD^1,2,3^*, Xavi Loinaz³^*, Sofia Wallin¹^*, Andrew Dunford³^*, Oliver Priebe³^*, Cody J. Boehner, BSc¹^*, Erica M. Horowitz, BA¹^*, Nang Kham Su, MSc¹^*, Hadley Barr, BSc¹^*, Laura Hevenor¹^*, Katherine Towle¹^*, Rashmika Beesam¹^*, Jenna D. Beckwith¹^*, Jacqueline Perry¹^*, David M. Cordas dos Santos, MD^1,2,3^*, Luca Bertamini, MD¹^*, Patricia Greipp, DO⁵, Kirsten Kübler, MD^3,6^*, Peter F. Arndt⁷^*, Carolina Terragna, PhD⁸^*, Elena Zamagni, MD⁹^*, Julian Hess³^*, Romanos Sklavenitis-Pistofidis, MD^1,2,3, Chip Stewart, PhD³^*, Gad Getz, PhD^2,3,10,11^* and Irene Ghobrial, MD^1,2,3

¹Dana-Farber Cancer Institute, Boston, MA
²Harvard Medical School, Boston, MA
³Broad Institute of MIT and Harvard, Cambridge, MA
⁴Department of Medical and Surgical Sciences - University of Bologna, Bologna, Italy
⁵Division of Hematopathology, Mayo Clinic, Rochester, MN
⁶Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, Germany
⁷Max Planck Institute for Molecular Genetics, Berlin, Germany
⁸IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy
⁹Istituto di Ematologia “Seràgnoli”, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
¹⁰Department of Pathology, Massachusetts General Hospital, Boston, MA
¹¹Krantz Family Center for Cancer Research and Dept. of Pathology, Massachusetts General Hospital, Boston, MA

5:45 PM

1020

Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies

Panagiotis Malandrakis, MD¹^*, Ioannis V Kostopoulos, PhD²^*, Ioannis Ntanasis-Stathopoulos, MD, PhD, MSc¹^*, Irene Solia, MD¹^*, Foteini Theodorakakou, MD¹^*, Vasiliki Spiliopoulou, MD¹^*, Despina Fotiou, MD¹^*, Magdalini Migkou, MD¹^*, Nikolaos Kanellias¹^*, Maria Roussou, MD¹^*, Evangelos Eleutherakis-Papaiakovou, MD¹^*, Kostantina Taouxi¹^*, Alexandra Papadimou¹^*, Christine-Ivy Liacos, MS¹^*, Maria Gavriatopoulou¹^*, Meletios-Athanasios Dimopoulos¹, Ourania Tsitsilonis, MD, PhD²^*, Evangelos Terpos, MD, PhD¹ and Efstathios Kastritis, MD¹^*

¹Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
²Department of Biology, School of Science, National and Kapodistrian University of Athens (NKUA), Athens, Greece

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

652.O2.6 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Genes, Cells and Algorithms: Novel Methods of Predicting Progression in MGUS and SMM